JP2024150445A5 - - Google Patents

Download PDF

Info

Publication number
JP2024150445A5
JP2024150445A5 JP2024099523A JP2024099523A JP2024150445A5 JP 2024150445 A5 JP2024150445 A5 JP 2024150445A5 JP 2024099523 A JP2024099523 A JP 2024099523A JP 2024099523 A JP2024099523 A JP 2024099523A JP 2024150445 A5 JP2024150445 A5 JP 2024150445A5
Authority
JP
Japan
Prior art keywords
antigen
binding protein
seq
pharmaceutical composition
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024099523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024150445A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/051610 external-priority patent/WO2019056023A2/en
Application filed filed Critical
Publication of JP2024150445A publication Critical patent/JP2024150445A/ja
Publication of JP2024150445A5 publication Critical patent/JP2024150445A5/ja
Pending legal-status Critical Current

Links

JP2024099523A 2017-09-18 2024-06-20 クローディン６抗体及びがんを治療するための方法 Pending JP2024150445A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
US62/560,143 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER
JP2020515692A JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020515692A Division JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法

Publications (2)

Publication Number Publication Date
JP2024150445A JP2024150445A (ja) 2024-10-23
JP2024150445A5 true JP2024150445A5 (https=) 2026-02-06

Family

ID=65723110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515692A Active JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法
JP2024099523A Pending JP2024150445A (ja) 2017-09-18 2024-06-20 クローディン６抗体及びがんを治療するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020515692A Active JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法

Country Status (22)

Country Link
US (4) US20200291111A1 (https=)
EP (2) EP4435009A3 (https=)
JP (2) JP7599332B2 (https=)
KR (2) KR20250050137A (https=)
CN (2) CN118667021A (https=)
AU (2) AU2018334434B2 (https=)
BR (1) BR112020005196A2 (https=)
CA (1) CA3076207A1 (https=)
CZ (1) CZ2021138A3 (https=)
DK (1) DK3826667T3 (https=)
ES (1) ES2986343T3 (https=)
FI (1) FI3826667T3 (https=)
GB (1) GB202103867D0 (https=)
HU (1) HUE067603T2 (https=)
IL (2) IL273196B2 (https=)
MX (2) MX2020002921A (https=)
NO (1) NO20210351A1 (https=)
PL (1) PL3826667T3 (https=)
PT (1) PT3826667T (https=)
SG (1) SG11202002114RA (https=)
SI (1) SI3826667T1 (https=)
WO (1) WO2019056023A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL273196B2 (en) * 2017-09-18 2024-11-01 Univ California Claudin6 antibodies and methods of treating cancer
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
JP7682797B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
AU2020241896A1 (en) * 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
KR20240153421A (ko) * 2022-02-09 2024-10-22 세라 프로그노스틱스 인코포레이티드 Shbg 및 ibp4 항체 및 이를 사용하는 방법
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
JP5632582B2 (ja) * 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9321842B2 (en) * 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
PE20160870A1 (es) * 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
SI3126381T2 (sl) * 2014-04-01 2022-05-31 Biontech Cell&Gene Therapies Gmbh Claudin-6-specifični imunoreceptorji in t-celični epitopi
IL273196B2 (en) * 2017-09-18 2024-11-01 Univ California Claudin6 antibodies and methods of treating cancer

Similar Documents

Publication Publication Date Title
JP2024150445A5 (https=)
JP2023051986A (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
JP7784511B2 (ja) 抗ネクチン－４抗体、それを含むコンジュゲート、及びその適用
JP2003525061A5 (https=)
CN107735093A (zh) Cd123抗体和其结合物
WO2023025243A1 (zh) 抗Nectin-4抗体、药物缀合物及其制备方法和用途
CN111655290A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
EP4658676A2 (en) Anti-cdh17 antibodies and use of the same
JP2023516195A (ja) Ｃ１９ ｃ３８二特異性抗体
US11110179B2 (en) Combination of CD33 antibody drug conjugates with chemotherapeutic agents
US20180296691A1 (en) Anti-efna4 antibody-drug conjugates
WO2023065594A1 (zh) 抗cd47-cldn18.2双特异性抗体及其用途
CN112996540B (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
JPWO2022090353A5 (https=)
JPWO2019228514A5 (https=)
JP2022530063A (ja) 抗体製剤
US20250092152A1 (en) Humanized antibody capable of binding to heg1 protein
CN120077073A (zh) 用于治疗里希特氏综合征的针对cd3和cd20的双特异性抗体
CN120695174A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
JPWO2023061505A5 (https=)
TWI922217B (zh) 用於治療類風濕性關節炎的抗體及其用途
JP7815590B2 (ja) ビメンチンを発現する腫瘍を治療するためのキットおよび容器
JPWO2022031710A5 (https=)
CN120435319A (zh) 抗-avb6抗体和抗体-药物缀合物及其在癌症治疗中的用途
TW202241505A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法